文献速递鼻科

Broncho-Vaxom®(OM-85 BV)可溶性成分刺激鼻窦先天免疫

Broncho-Vaxom® (OM-85 BV) soluble components stimulate sinonasal innate immunity.
PubMed 文献 · Int Forum Allergy Rhinol · 2019-01-07

该体外研究将人鼻窦上皮细胞在气液界面培养,观察OM-85 BV刺激后纤毛摆动频率与一氧化氮生成的变化。结果显示顶端给予OM-85 BV引起一氧化氮介导的纤毛摆动频率增加(p < 0.05)和一氧化氮生成增加(p < 0.0001);苦味受体通路抑制剂可阻断上述一氧化氮增加。作者认为OM-85 BV具有纤毛刺激和免疫原性,部分解释其呼吸道治疗作用,但需进一步研究。

要点

  • OM-85 BV顶端刺激使鼻窦上皮细胞一氧化氮生成增加(p < 0.0001)。
  • OM-85 BV引起一氧化氮介导的纤毛摆动频率增加(p < 0.05)。
  • 苦味受体通路抑制剂可阻断OM-85 BV诱导的一氧化氮增加。

核心结论

  • OM-85 BV具有纤毛刺激和免疫原性,可能部分解释其作为呼吸道治疗药物的疗效。
  • 上述反应依赖一氧化氮,并与苦味受体T2R激活一致。
  • 需进一步研究以阐明具体成分与受体的信号关系。

研究设计与样本

  • 体外研究:人鼻窦上皮细胞在气液界面培养,检测OM-85 BV刺激后纤毛摆动频率和一氧化氮生成,并使用苦味受体信号药理抑制剂。

主要发现

  • 与生理盐水刺激的对照培养相比,顶端给予OM-85 BV引起一氧化氮介导的纤毛摆动频率增加(p < 0.05)。
  • 与生理盐水刺激的对照培养相比,顶端给予OM-85 BV引起一氧化氮生成增加(p < 0.0001)。
  • 气液界面培养预先用苦味受体通路抑制剂处理,可阻断OM-85 BV诱导的一氧化氮增加。

关键数值与推荐

  • OM-85 BV是感染性呼吸道细菌提取物,在美国以外用于支气管炎和鼻窦炎的预防和治疗。
  • 既往研究显示使用OM-85 BV与呼吸道感染频率降低和抗生素使用时间缩短相关。

局限性

  • 需进一步研究以阐明具体成分与受体的信号关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Broncho-Vaxom® (OM-85 BV) is an extract of infectious respiratory bacteria that is used as an immunostimulant outside of the United States for the prevention and treatment of bronchitis and rhinosinusitis. Prior studies have shown that use of OM-85 BV is associated with reduction in frequency of respiratory infection and decreased duration of antibiotic usage. However, the effects of OM-85 BV on respiratory mucosal innate immunity are unknown. METHODS: Human sinonasal epithelial cells were grown at an air-liquid interface (ALI). Ciliary beat frequency (CBF) and nitric oxide (NO) production in response to stimulation with OM-85 BV was measured in vitro. Pharmacologic inhibitors of bitter taste receptor (T2R) signaling were used to determine if this pathway was taste-receptor-mediated. RESULTS: Apical application of OM-85 BV resulted in an NO-mediated increase in CBF (p < 0.05) and increased NO production (p < 0.0001) when compared to saline-stimulated control cultures. ALI pretreatment with taste receptor pathway inhibitors blocked OM-85 BV-induced increases in NO. CONCLUSION: OM-85 BV has ciliostimulatory and immunogenic properties that may be partially responsible for its observed efficacy as a respiratory therapeutic. These responses were NO-dependent and consistent with T2R activation. Further work is necessary to elucidate specific component-receptor signaling relationships.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Triantafillou V, Workman AD, Patel NN, et al. Broncho-Vaxom® (OM-85 BV) soluble components stimulate sinonasal innate immunity. Int Forum Allergy Rhinol. 2019. PMID: 30615298. doi:10.1002/alr.22276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。